Checkpoint Trends Ltd
₹ 45.2
-1.87%
12 Mar
- close price
About
Incorporated in 1991, Checkpoint Trends Ltd is in the business of trading and consultancy[1]
Key Points
- Market Cap ₹ 24.7 Cr.
- Current Price ₹ 45.2
- High / Low ₹ 144 / 12.2
- Stock P/E 12.0
- Book Value ₹ 3.60
- Dividend Yield 0.00 %
- ROCE 16.5 %
- ROE 9.17 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 12.5 times its book value
- The company has delivered a poor sales growth of -12.8% over past five years.
- Company has a low return on equity of 0.00% over last 3 years.
- Company has high debtors of 212 days.
- Working capital days have increased from 220 days to 387 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0 | -0 | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 295 | |
| 0 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 292 | |
| Operating Profit | -0 | -0 | -0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | 3 |
| OPM % | -5% | 10% | -1% | -31% | 2% | 2% | -1% | -7% | 3% | 20% | 1% | ||
| -0 | -3 | -0 | -0 | -0 | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | |
| Interest | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 |
| Depreciation | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | 0 | 0 |
| Profit before tax | -0 | -3 | -0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | 3 |
| Tax % | -0% | -0% | -0% | -0% | -0% | -0% | 20% | -0% | 50% | -0% | -50% | 40% | |
| -0 | -3 | -0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | 2 | |
| EPS in Rs | -0.11 | -5.61 | -0.02 | 0.05 | -0.29 | -0.02 | 0.05 | 0.02 | -0.07 | -0.15 | 0.05 | 0.05 | 3.72 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -13% |
| 3 Years: | -37% |
| TTM: | 40822% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 38% |
| 3 Years: | 48% |
| TTM: | 810% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 84% |
| 3 Years: | 112% |
| 1 Year: | 174% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -1% |
| 3 Years: | 0% |
| Last Year: | 9% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | -2 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -4 |
| 0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | -0 | -0 | -0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 139 | |
| Total Liabilities | 4 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 141 |
| -0 | -0 | -0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | |
| CWIP | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Investments | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| 4 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 141 | |
| Total Assets | 4 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 141 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0 | -0 | -0 | 0 | 0 | -0 | 0 | 1 | -0 | 0 | -0 | 0 | |
| -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | |
| 0 | -0 | -0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | |
| Net Cash Flow | 0 | -0 | -0 | 0 | 0 | -0 | -0 | 1 | -0 | 0 | -0 | 0 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 36 | 24 | 54 | 179 | 107 | 164 | 122 | 135 | 229 | 212 | ||
| Inventory Days | -0 | -0 | -0 | -0 | -0 | -0 | -0 | |||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 36 | 24 | 54 | 179 | 107 | 164 | 122 | 135 | 229 | 212 | ||
| Working Capital Days | 18 | -35 | 36 | 260 | 221 | 60 | 98 | 129 | 145 | 387 | ||
| ROCE % | -2% | -3% | -3% | 7% | 25% | -31% | 3% | 2% | -3% | -13% | 3% | 17% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Electricity Consumption Cost INR |
|
|||||||||||
| Debtors Turnover Ratio Ratio |
||||||||||||
| Number of Shareholders Count |
||||||||||||
| Percentage of Shares in Dematerialized Form % |
||||||||||||
| Number of Permanent Employees Count |
||||||||||||
Requires Premium
Requires Premium
Documents
Announcements
-
Board Meeting Intimation for The Meeting Of Board Of The Company Is Scheduled To Be Held On Wednesday, March 18, 2026
2d - Board meeting on March 18, 2026 to consider resignation and appointment of independent director; trading window closed from March 10.
-
Board Meeting Outcome for Subject: Outcome Of The Board Meeting For Allotment Of 1,66,74,072 (One Crores Sixty Six Lakhs Seventy Four Thousand Seventy Two) Convertible Warrants ('Warrants').
5 Mar - Allotted 1,66,74,072 warrants at Rs45.01 each, raising Rs75.05 crore, March 5, 2026.
-
Announcement under Regulation 30 (LODR)-Allotment
5 Mar - Allotment of 1,66,74,072 warrants at ₹45.01 each, raising ₹75.05 crore; 25% received.
-
Cancellation Of Board Meeting
25 Feb - Board meeting scheduled February 25, 2026 cancelled; company to inform revised date if any.
-
Board Meeting Intimation for Intimation Of Board Meeting For The Meeting To Be Held On February 25, 2026
20 Feb - Board meeting Feb 25, 2026: WTD resignation, new WTD appointment, acquisition proposal, related-party transaction; trading window closed.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
CTL (Formerly Rubra Medicaments Ltd) was engaged in the manufacture and sale of pharmaceutical formulations based in Hyderabad. The company is currently in the business of trading and providing different kinds of consulting services in India to all categories of clients.